A Phase I/II Study of MK-3475 with Gemcitabine in Patients with Previously-Treated Advanced Non-small Cell Lung Cancer (NSCLC)
This study is an open-label, non-randomized phase I study, followed by open-label non-randomized phase II study. The first cohort of patients will receive 200 milligrams (mg) of MK-3475 by intravenous infusion over a 21-day period called a cycle along with gemcitabine 1250 mg/m2 given on Days 1 and 8 of each 21-day cycle for up to 6 cycles. Patients will be seen in the study clinic 12 times over 126 days for an evaluation of signs and symptoms that may represent drug toxicity. Patients may continue to receive MK-3475 (without gemcitabine) for up to 2 years.
* Women or men with advanced, histologically proven NSCLC.
* Patients must have received at least one but no more than three prior systemic therapies for advanced disease.
* Any toxicity related to prior therapies that, in the opinion of the investigator, would potentially be worsened with anti-PD1 therapy or gemcitabine should be resolved to less than Grade 1.
* Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1.
Prior therapy with any anti-PD-1, anti-PD-L1, or anti-CTLA4 antibody.
Prior therapy with gemcitabine.
Prior complications from radiation, such as history of radiation pneumonitis or pulmonary edema that, in the opinion of the investigator, may have risk of increasing toxicity with anti-PD1 therapy.
Active autoimmune disease except vitiligo or stable hypothyroidism.
Active and ongoing steroid use, except for non-systemically absorbed treatments (such as inhaled or topical steroid therapy for asthma, cardiopulmonary disease (COPD), allergic rhinitis).
Rachel Sanborn, M.D.
Earle A Chiles Research Institute (EACRI)
- Oncology and Hematology Care Eastside
- Oncology and Hematology Care Westside